Eric Ko to Female
This is a "connection" page, showing publications Eric Ko has written about Female.
Connection Strength
0.079
-
Ko EC, Genden EM, Misiukiewicz K, Som PM, Kostakoglu L, Chen CT, Packer S, Kao J. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep. 2012 Feb; 27(2):467-74.
Score: 0.021
-
Ko EC, Koprowski CD, Dickson-Witmer D, Penman E, Sorensen M, Hanlon AL, Sammons S, Farach A, Strasser J. Partial vs. whole breast irradiation in a community hospital: a retrospective cohort analysis of 200 patients. Brachytherapy. 2010 Jul-Sep; 9(3):248-53.
Score: 0.019
-
Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res. 2007 Aug 15; 67(16):7875-84.
Score: 0.016
-
Carpenter TJ, Kann B, Buckstein MH, Ko EC, Bakst RL, Misiukiewicz KJ, Posner MR, Genden EM, Gupta V. Tolerability, toxicity, and temporal implications of transoral robotic surgery (TORS) on adjuvant radiation therapy in carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 2014 Nov; 123(11):791-7.
Score: 0.006
-
D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10.
Score: 0.006
-
Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One. 2012; 7(6):e36979.
Score: 0.006
-
Tong CC, Lau KH, Rivera M, Cannan D, Aguirre-Ghiso J, Sikora AG, Gupta V, Forsythe K, Ko EC, Misiukiewicz K, Gurudutt V, Teng MS, Packer SH, Genden EM, Kao J. Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. 2012 May; 27(5):1580-6.
Score: 0.005